Back to Search
ANJALI OZA, M.D.
M.D.
Hospitalist Physician
NPI: 1417158098Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
036130321(IL)
Hospitalist PhysicianPrimary
Hospitalist
Code: 208M00000X
036130321(IL)
Research & Publications (20)
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
PMID 18591547·J Clin Oncol·2008
3-trial
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
PMID 19135709·Gynecol Oncol·2009
3-trial
Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
PMID 19451434·J Clin Oncol·2009
3-trial
Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
PMID 19029964·Bone Marrow Transplant·2009
3-trial
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
PMID 19520420·Gynecol Oncol·2009
3-trial
Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
PMID 19383817·Clin Cancer Res·2009
3-trial
Performance of dedicated versus integrated bipolar defibrillator leads with CRT-defibrillators: results from a Prospective Multicenter Study.
PMID 19170903·Pacing Clin Electrophysiol·2009
4-observational
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
PMID 19476988·Gynecol Oncol·2009
3-trial
Laboratory diagnosis of Clostridium difficile-associated disease in the Republic of Ireland: a survey of Irish microbiology laboratories.
PMID 18353502·J Hosp Infect·2008
8-other
Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents.
PMID 18323557·J Clin Oncol·2008
8-other
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
PMID 18423560·Gynecol Oncol·2008
3-trial
Campylobacter spp. in conventional broiler flocks in Northern Ireland: epidemiology and risk factors.
PMID 18249451·Prev Vet Med·2008
7-preclinical
Hospital infection society prevalence survey of Healthcare Associated Infection 2006: comparison of results between Northern Ireland and the Republic of Ireland.
PMID 18547678·J Hosp Infect·2008
4-observational
Polaron hopping in some biomolecular solids and their charge transfer complexes.
PMID 19239130·Indian J Biochem Biophys·2008
8-other
A rare case of ectopic adrenocorticotropic hormone syndrome in small cell carcinoma of the vagina: a case report.
PMID 18369310·J Low Genit Tract Dis·2008
5-case
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
PMID 19010874·Clin Cancer Res·2008
3-trial
Optimization of superior vena cava coil position and usage for transvenous defibrillation.
PMID 18313597·Heart Rhythm·2008
4-observational
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
PMID 18519776·Clin Cancer Res·2008
3-trial
Molecular targeted agents combined with chemo-radiation in the treatment of locally advanced cervix cancer.
PMID 18474021·Rev Recent Clin Trials·2008
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 25 N WINFIELD RD, STE 400
WINFIELD, IL 60190 - Phone
- (630) 469-9200
Quick Facts
- NPI
- 1417158098
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile